Overview

A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Evaluate the safety, tolerability and pharmacokinetics of ABT-288 in order to determine the maximum tolerated dose of ABT-288 in stable schizophrenic volunteers receiving treatment with an atypical antipsychotic.
Phase:
Phase 1
Details
Lead Sponsor:
Abbott
AbbVie